oxybutynin has been researched along with Bladder Diseases in 64 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oxybutynin chloride (Ditropan) and placebo were randomized in a double-blind trial to determine the effectiveness of the test agent in controlling post-transurethral pain and spasm." | 9.04 | Oxybutynin chloride in control of post-trasurethral vesical pain and spasm. ( Paulson, DF, 1978) |
| "A double-blind study of the short-term effects of oxybutynin chloride versus placebo on bladder spasm after transurethral surgery was done in 106 male patients." | 9.04 | Effect of oxybutynin chloride on bladder spasm following transurethral surgery. ( Benson, GS; Hanno, PM; Raezer, DM; Wein, AJ, 1978) |
| "To evaluate the symptomatic and urodynamic effects of oxybutynin in the control of irritative micturitional symptoms during the first week after transurethral resection of benign prostatic hyperplasia (BPH)." | 5.08 | Oxybutynin in the treatment of early detrusor instability after transurethral resection of the prostate. ( Borst, F; Graber, P; Iselin, CE; Rohner, S; Schmidlin, F, 1997) |
| "Oxybutynin chloride (Ditropan) and placebo were randomized in a double-blind trial to determine the effectiveness of the test agent in controlling post-transurethral pain and spasm." | 5.04 | Oxybutynin chloride in control of post-trasurethral vesical pain and spasm. ( Paulson, DF, 1978) |
| "A double-blind study of the short-term effects of oxybutynin chloride versus placebo on bladder spasm after transurethral surgery was done in 106 male patients." | 5.04 | Effect of oxybutynin chloride on bladder spasm following transurethral surgery. ( Benson, GS; Hanno, PM; Raezer, DM; Wein, AJ, 1978) |
| " Peak plasma concentrations of oxybutynin and the major active metabolite, N-desethyloxybutynin, are reached 24 - 48 hours after a single application and therapeutic concentrations are maintained throughout the dosage interval." | 2.71 | Transdermal oxybutynin: for overactive bladder. ( Bang, LM; Easthope, SE; Perry, CM, 2003) |
| "Accelerated intravesical administration results in greater bioavailability and increased objective benefits without side effects in previously unresponsive patients compared with oral and intravesical passive diffusion oxybutynin administration." | 2.70 | Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens. ( Capelli, G; Di Stasi, SM; Giannantoni, A; Massoud, R; Navarra, P; Stephen, RL; Vespasiani, G, 2001) |
| " New antimuscarinic anticholinergic medications have improved the treatment of OAB, offering patients efficacy equal to that of immediate-release oxybutynin with fewer side effects and an improved dosing schedule." | 2.42 | Overactive bladder: improving the efficacy of anticholinergics by dose escalation. ( MacDiarmid, SA, 2003) |
| " Controlled drug delivery systems seen in commercially available OAB formulations alter the pharmacokinetics of antimuscarinic medications in ways that maintain efficacy and allow once-daily dosing and reduction of adverse events." | 2.41 | New perspectives on the overactive bladder: pharmacokinetics and bioavailability. ( Gupta, S; Mori, T; Sathyan, G, 2002) |
| " Similarly, the potential improvements in tolerability associated with different dosage formulations of oxybutynin, and the clinical utility of S-oxybutynin, are yet to be conclusively demonstrated." | 2.41 | Muscarinic receptor antagonists in the treatment of overactive bladder. ( Chapple, CR, 2000) |
| "Resiniferatoxin (RTX) is an ultrapotent capsaicin analog that has the significant advantage of being a nonirritant." | 2.41 | Intravesical treatment of overactive bladder. ( Fowler, CJ, 2000) |
| "Oxybutynin is a tertiary amine, which undergoes an extensive first-pass metabolism." | 2.41 | Oxybutynin and the overactive bladder. ( Andersson, KE; Chapple, CR, 2001) |
| " The convenience of once-daily dosing of antimuscarinic agents would be expected to improve patient compliance and further relieve the symptoms of OAB." | 2.41 | Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. ( Rovner, ES; Wein, AJ, 2002) |
| " OH is well absorbed from the bladder, however absorption seems to be protracted compared to oral intake." | 1.28 | Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride. ( Jilg, G; Madersbacher, H, 1991) |
| "Oxybutynin has been widely prescribed in the United Kingdom for more than 5 years on a named patient basis." | 1.27 | Oxybutynin: is it safe? ( Baigrie, RJ; Fawcett, DP; Kelleher, JP; Pengelly, AW, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (14.06) | 18.7374 |
| 1990's | 14 (21.88) | 18.2507 |
| 2000's | 40 (62.50) | 29.6817 |
| 2010's | 1 (1.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kapoor, H | 1 |
| Gupta, E | 1 |
| Sood, A | 1 |
| Götz, AK | 1 |
| Reinhold, SW | 1 |
| Szecsey, A | 1 |
| Banas, B | 1 |
| Krämer, BK | 1 |
| Newman, DK | 1 |
| Patel, HR | 1 |
| Albehussi, S | 1 |
| Arya, M | 1 |
| Miller, RA | 1 |
| Appell, RA | 2 |
| Lai, HH | 1 |
| Boone, TB | 1 |
| Staskin, DR | 2 |
| Gupta, S | 1 |
| Sathyan, G | 1 |
| Mori, T | 1 |
| Dmochowski, RR | 2 |
| Beneton, C | 1 |
| De Parisot, O | 1 |
| Halaska, M | 1 |
| Ralph, G | 1 |
| Wiedemann, A | 1 |
| Primus, G | 1 |
| Ballering-Brühl, B | 1 |
| Höfner, K | 1 |
| Jonas, U | 1 |
| Malone-Lee, J | 2 |
| Henshaw, DJ | 1 |
| Cummings, K | 1 |
| Bang, LM | 1 |
| Easthope, SE | 1 |
| Perry, CM | 1 |
| Chancellor, M | 1 |
| Wagg, A | 2 |
| Rovner, ES | 2 |
| Wein, AJ | 3 |
| Homma, Y | 2 |
| Paick, JS | 1 |
| Lee, JG | 2 |
| Kawabe, K | 1 |
| Scarpero, HM | 1 |
| MacDiarmid, SA | 1 |
| Martín-Crespo, R | 1 |
| Luque, R | 1 |
| Getsios, D | 1 |
| Caro, JJ | 1 |
| Ishak, KJ | 1 |
| El-Hadi, W | 1 |
| Payne, K | 1 |
| Uemura, S | 1 |
| Oki, T | 2 |
| Kimura, R | 1 |
| Saito, M | 2 |
| Miyagawa, I | 2 |
| Yamada, S | 2 |
| Toma-Okura, A | 1 |
| Agarwal, A | 1 |
| Dhiraaj, S | 1 |
| Singhal, V | 1 |
| Kapoor, R | 1 |
| Tandon, M | 1 |
| Bonney, WW | 1 |
| Robinson, RA | 1 |
| Theobald, RJ | 1 |
| Bensman, A | 1 |
| Deschenes, G | 1 |
| Audry, G | 1 |
| Grapin, C | 1 |
| Iselin, CE | 1 |
| Schmidlin, F | 1 |
| Borst, F | 1 |
| Rohner, S | 1 |
| Graber, P | 1 |
| Kelleher, CJ | 1 |
| Cardozo, LD | 2 |
| Khullar, V | 1 |
| Salvatore, S | 1 |
| Chai, TC | 1 |
| Kwak, TI | 1 |
| Bayliss, M | 1 |
| Ingham, NJ | 1 |
| Arnold, K | 1 |
| Kelly, PM | 1 |
| Baxter, GM | 1 |
| Chapple, CR | 2 |
| Fowler, CJ | 1 |
| Serrano Brambila, EA | 1 |
| Quiroga Avila, RG | 1 |
| Lorenzo Monterrubio, JL | 1 |
| Moreno Aranda, J | 1 |
| Kamo, I | 1 |
| Imai, S | 1 |
| Okanishi, S | 1 |
| Doi, T | 1 |
| Tabuchi, F | 1 |
| Otsubo, K | 1 |
| Di Stasi, SM | 1 |
| Giannantoni, A | 1 |
| Vespasiani, G | 1 |
| Navarra, P | 1 |
| Capelli, G | 1 |
| Massoud, R | 1 |
| Stephen, RL | 1 |
| Nilvebrant, L | 1 |
| Lose, G | 1 |
| Nørgaard, JP | 1 |
| Hartnett, NM | 1 |
| Saver, BG | 1 |
| Weiss, BD | 1 |
| Zimmern, P | 1 |
| Andersson, KE | 1 |
| Cannon, TW | 1 |
| Chancellor, MB | 1 |
| Paulson, DF | 1 |
| Hanno, PM | 1 |
| Raezer, DM | 1 |
| Benson, GS | 1 |
| Madersbacher, H | 1 |
| Jilg, G | 1 |
| Koonings, PP | 1 |
| Bergman, A | 1 |
| Tapp, AJ | 1 |
| Versi, E | 1 |
| Cooper, D | 1 |
| Kontani, H | 1 |
| Nakagawa, M | 1 |
| Takeno, S | 1 |
| Sakai, T | 1 |
| Moore, KH | 2 |
| Hay, DM | 1 |
| Imrie, AE | 1 |
| Watson, A | 1 |
| Goldstein, M | 1 |
| Sutherst, JR | 1 |
| Holmes, DM | 1 |
| Montz, FJ | 1 |
| Stanton, SL | 1 |
| Baigrie, RJ | 1 |
| Kelleher, JP | 1 |
| Fawcett, DP | 1 |
| Pengelly, AW | 1 |
| Ouslander, JG | 1 |
| Blaustein, J | 1 |
| Connor, A | 1 |
| Pitt, A | 1 |
| Fanciullacci, F | 1 |
| Zanollo, A | 1 |
| Sandri, S | 1 |
| Catanzaro, F | 1 |
| Kirkali, Z | 1 |
| Whitaker, RH | 1 |
| Mundy, AR | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Pregabalin Administration on Catheter- Related Bladder Discomfort in Orthopedic Surgical Operations[NCT03232021] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2017-08-16 | Withdrawn (stopped due to All patients during the study period were subjected to peripheral blocks or were excluded from the study due to exclusion criteria) | ||
| Effect of Pregabalin Administration on Catheter- Related Bladder Discomfort in Urological Surgical Operations[NCT03229668] | Phase 2/Phase 3 | 78 participants (Actual) | Interventional | 2017-07-28 | Completed | ||
| Comparative Study of Safety and Efficacy Between 100 U Suburothelial Injection and 50 U Suburothelial Plus 50 U Urethral Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility[NCT02135341] | Phase 2 | 60 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome - A Prospective Randomized Controlled Comparative Study With Mono-antimuscarinic Therapy[NCT01824420] | Phase 4 | 129 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Incobotulinumtoxin Versus Onabotulinumtoxin in the Treatment of Patients With Overactive Bladder Syndrome[NCT03758235] | Phase 3 | 140 participants (Actual) | Interventional | 2018-09-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for oxybutynin and Bladder Diseases
| Article | Year |
|---|---|
Chronic pelvic ischemia: etiology, pathogenesis, clinical presentation and management.
Topics: Aged; Animals; Atherosclerosis; Calcium; Cell Hypoxia; Chronic Pain; Disease Models, Animal; Estroge | 2014 |
Pharmacologic treatment for detrusor overactivity.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Muscarinic Antagonis | 2002 |
New perspectives on the overactive bladder: pharmacokinetics and bioavailability.
Topics: Administration, Cutaneous; Administration, Oral; Benzhydryl Compounds; Biological Availability; Chol | 2002 |
Future studies of overactive bladder: the need for standardization.
Topics: Adult; Child; Cholinergic Antagonists; Female; Forecasting; Humans; Mandelic Acids; Muscarinic Antag | 2002 |
[The medical treatment of overactive bladder].
Topics: Clinical Trials as Topic; Humans; Mandelic Acids; Muscarinic Antagonists; Urinary Bladder Diseases; | 2003 |
Update on overactive bladder: pharmacologic approaches on the horizon.
Topics: Administration, Cutaneous; Administration, Intravesical; Administration, Oral; Adrenergic beta-3 Rec | 2003 |
Muscarinic receptors: what we know.
Topics: Animals; Central Nervous System; Heart; Humans; Mandelic Acids; Muscarinic Antagonists; Muscle, Smoo | 2003 |
Overactive bladder: improving the efficacy of anticholinergics by dose escalation.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Dose-Response Relationship, Drug; Humans; Ma | 2003 |
[Bladder dysfunction in children].
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Infant; Male; Mandelic Acids; Parasympatholytic | 1995 |
Muscarinic receptor antagonists in the treatment of overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Clinical Trials as Topic; Cresols; Humans; Mandelic Acids; Muscar | 2000 |
Muscarinic receptor antagonists in the treatment of overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Clinical Trials as Topic; Cresols; Humans; Mandelic Acids; Muscar | 2000 |
Muscarinic receptor antagonists in the treatment of overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Clinical Trials as Topic; Cresols; Humans; Mandelic Acids; Muscar | 2000 |
Muscarinic receptor antagonists in the treatment of overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Clinical Trials as Topic; Cresols; Humans; Mandelic Acids; Muscar | 2000 |
Intravesical treatment of overactive bladder.
Topics: Administration, Intravesical; Anesthetics, Local; Atropine; Capsaicin; Cholinergic Antagonists; Dite | 2000 |
Clinical experiences with tolterodine.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Cresols; Dose-Response Relationship, Drug; | 2001 |
Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor.
Topics: Administration, Intravesical; Child; Cholinergic Antagonists; Humans; Mandelic Acids; Spinal Cord In | 2001 |
Oxybutynin and the overactive bladder.
Topics: Humans; Mandelic Acids; Muscarinic Antagonists; Urinary Bladder; Urinary Bladder Diseases | 2001 |
Pharmacotherapy of the overactive bladder and advances in drug delivery.
Topics: Administration, Intravesical; Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Botulinum Toxi | 2002 |
Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review.
Topics: Administration, Oral; Adult; Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Drug | 2002 |
14 trials available for oxybutynin and Bladder Diseases
| Article | Year |
|---|---|
Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability.
Topics: Adult; Aged; Aged, 80 and over; Benzilates; Double-Blind Method; Female; Follow-Up Studies; Humans; | 2003 |
Transdermal oxybutynin: for overactive bladder.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Benzhydryl Compounds; Cresols; Double- | 2003 |
Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-B | 2003 |
Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
Topics: Adult; Anti-Infective Agents, Urinary; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; H | 2006 |
Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
Topics: Adult; Anti-Infective Agents, Urinary; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; H | 2006 |
Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
Topics: Adult; Anti-Infective Agents, Urinary; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; H | 2006 |
Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
Topics: Adult; Anti-Infective Agents, Urinary; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; H | 2006 |
Oxybutynin in the treatment of early detrusor instability after transurethral resection of the prostate.
Topics: Aged; Double-Blind Method; Humans; Male; Mandelic Acids; Middle Aged; Parasympatholytics; Postoperat | 1997 |
[Assessment of effectiveness of and tolerance to oxybutynin in the treatment of unstable bladder in women].
Topics: Adult; Aged; Aged, 80 and over; Cholinergic Antagonists; Cross-Sectional Studies; Double-Blind Metho | 2000 |
Treatment of overactive bladder with modified intravesical oxybutynin chloride.
Topics: Administration, Intravesical; Adolescent; Aged; Cholinergic Antagonists; Drug Administration Schedul | 2000 |
Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens.
Topics: Administration, Intravesical; Adolescent; Adult; Autonomic Dysreflexia; Cholinergic Antagonists; Ele | 2001 |
Oxybutynin chloride in control of post-trasurethral vesical pain and spasm.
Topics: Clinical Trials as Topic; Cyclohexanes; Double-Blind Method; Female; Humans; Male; Mandelic Acids; P | 1978 |
Effect of oxybutynin chloride on bladder spasm following transurethral surgery.
Topics: Aged; Clinical Trials as Topic; Cyclohexanes; Double-Blind Method; Drug Evaluation; Humans; Male; Ma | 1978 |
The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Mandelic Acids; Menopause; Middle Aged | 1990 |
Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability.
Topics: Double-Blind Method; Female; Humans; Mandelic Acids; Middle Aged; Parasympatholytics; Urinary Bladde | 1990 |
Response to treatment of detrusor instability in relation to psychoneurotic status.
Topics: Colonic Diseases, Functional; Double-Blind Method; Enuresis; Female; Humans; Life Change Events; Man | 1990 |
Oxybutinin versus propantheline in the management of detrusor instability. A patient-regulated variable dose trial.
Topics: Adult; Aged; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Mandelic Ac | 1989 |
34 other studies available for oxybutynin and Bladder Diseases
| Article | Year |
|---|---|
Severe anticholinergic drug-induced delirium in a young adult after renal transplantation.
Topics: Adult; Cholinergic Antagonists; Delirium; Humans; Kidney Transplantation; Male; Mandelic Acids; Para | 2009 |
New treatment options for overactive bladder and incontinence.
Topics: Aged; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Geriatric Assessment; Geriatric Nursin | 2002 |
Can oxybutynin cause peripheral neuropathy?
Topics: Administration, Intravesical; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2002 |
Treatment of overactive bladder: the Antimuscarinic Clinical Effectiveness Trial.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Muscarinic Antagonis | 2002 |
Methodologic shortcomings inherent in a post-hoc analysis.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Clinical Trials as Topic; Cresols; Humans; Mandelic A | 2002 |
Oxybutynin transdermal (Oxytrol) for overactive bladder.
Topics: Administration, Cutaneous; Administration, Oral; Benzhydryl Compounds; Cresols; Delayed-Action Prepa | 2003 |
Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Mandelic Acids; Middle Aged; Muscarinic Antagonists; | 2003 |
Transdermal oxybutynin. A viewpoint by Michael Chancellor.
Topics: Administration, Cutaneous; Delayed-Action Preparations; Erythema; Humans; Mandelic Acids; Pruritus; | 2003 |
Transdermal oxybutynin. A viewpoint by Adrian Wagg.
Topics: Administration, Cutaneous; Adult; Aged; Delayed-Action Preparations; Humans; Mandelic Acids; Skin; U | 2003 |
[In which patients is the oxybutynin-desmopressin combination therapy indicated?].
Topics: Adolescent; Child; Deamino Arginine Vasopressin; Drug Therapy, Combination; Female; Humans; Male; Ma | 2003 |
Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder.
Topics: Benzhydryl Compounds; Canada; Costs and Cost Analysis; Cresols; Delayed-Action Preparations; Female; | 2004 |
Use of the short form of King's Health Questionnaire to measure quality of life in patients with an overactive bladder.
Topics: Aged; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Male; Mandelic Acids; Mult | 2004 |
Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder.
Topics: Administration, Intravesical; Animals; Male; Mandelic Acids; Rats; Rats, Sprague-Dawley; Receptors, | 2004 |
Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Male; Mandelic Acids; N-Methylscopolamine; | 2006 |
Topical effect of intravesical oxybutynin.
Topics: Administration, Intravesical; Animals; Female; Mandelic Acids; Parasympatholytics; Rats; Ulcer; Urin | 1993 |
A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance.
Topics: Adult; Aged; Aged, 80 and over; Cholinergic Antagonists; Exercise Therapy; Female; Humans; Incontine | 1997 |
This month in investigative urology: new insights into the clinical value of oxybutynin.
Topics: Cholinergic Antagonists; Humans; Mandelic Acids; Urinary Bladder Diseases | 1998 |
Inhibitory effects of propiverine, atropine and oxybutynin on bladder instability in rats with infravesical outlet obstruction.
Topics: Animals; Atropine; Benzilates; Female; Ligation; Mandelic Acids; Parasympatholytics; Pressure; Rats; | 1998 |
Urodynamic variables cannot be used to classify the severity of detrusor instability.
Topics: Female; Humans; Mandelic Acids; Middle Aged; Parasympatholytics; Pressure; Prospective Studies; Trea | 1998 |
Solitary fibrous tumour of the prostate.
Topics: Humans; Male; Mandelic Acids; Mesothelioma; Middle Aged; Muscarinic Antagonists; Prostatic Neoplasms | 1998 |
Possible site of action of TAK-637, a tachykinin NK(1) receptor antagonist, on the micturition reflex in guinea pigs.
Topics: Animals; Atropine; Benzhydryl Compounds; Benzilates; Carbachol; Cresols; Denervation; Dose-Response | 2000 |
Detrol LA and Diropan XL for overactive bladder.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Clinical Trials as Topic; Cresols; Delayed-Action Pre | 2001 |
Is extended-release oxybutynin (Ditropan XL) or tolterodine (Detrol) more effective in the treatment of an overactive bladder?
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Delayed-Action Preparations; Double-Blind Me | 2001 |
POEMS (patient-oriented evidence that matters) spark discussion.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Clinical Trials as Topic; Cresols; Delayed-Action Pre | 2001 |
Intravesical treatment of bladder dysfunction.
Topics: Administration, Intravesical; Cholinergic Antagonists; Humans; Mandelic Acids; Receptors, Opioid; Ur | 2001 |
Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride.
Topics: Administration, Intravesical; Adult; Female; Humans; Male; Mandelic Acids; Middle Aged; Parasympatho | 1991 |
Urethral pressure changes in women with detrusor instability. Bladder or urethral pathologic process?
Topics: Adult; Aged; Female; Humans; Mandelic Acids; Middle Aged; Muscle Contraction; Muscle, Smooth; Parasy | 1991 |
Evaluation of drugs for treatment of urinary bladder dysfunction in conscious rats with intact pelvic nerve and after resection of the left pelvic nerve.
Topics: Animals; Atropine; Butylamines; Decerebrate State; Drug Evaluation; Male; Mandelic Acids; Nifedipine | 1990 |
Oxybutynin: is it safe?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Humans; Male; Mandelic Acids; Middle Aged | 1988 |
Habit training and oxybutynin for incontinence in nursing home patients: a placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Bacteriuria; Drug Evaluation; Female; Humans; Male; Mandelic Acids; Nursing | 1988 |
The neuropathic bladder in children with spinal cord injury.
Topics: Catheterization; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Kidney Diseases; Male; | 1988 |
The use of oxybutynin in urological practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Combined Modality Therapy; Fema | 1987 |
The unstable bladder.
Topics: Cystoscopy; Diagnosis, Differential; Female; Humans; Male; Mandelic Acids; Parasympatholytics; Psych | 1985 |
The unstable bladder.
Topics: Female; Humans; Imipramine; Mandelic Acids; Propantheline; Psychotherapy; Urinary Bladder; Urinary B | 1985 |